) reported adjusted net earnings of $128.1 million or 36 cents
per share for the fourth quarter of 2013, topping the Zacks
Consensus Estimate of 34 cents per share. This reflected a 14.6%
rise from $111.8 million and 12.5% from 32 cents in the
comparable quarter a year ago.
ATHENAHEALTH IN (ATHN): Free Stock Analysis
CERNER CORP (CERN): Free Stock Analysis
ALLSCRIPTS HLTH (MDRX): Free Stock Analysis
QUALITY SYS (QSII): Free Stock Analysis
To read this article on Zacks.com click here.
However, reported net earnings fell 46.3% to $60.1 million from
$111.8 million in the fourth quarter of 2012 while earnings per
share dipped 46.9% to 17 cents from 32 cents in the year-ago
Revenues in the quarter grew roughly 12% to $795.3 million,
exceeding the Zacks Consensus Estimate of $793 million. Global
revenues went up 8% for the quarter. The increase can be
attributed to stronger revenues from Support, maintenance and
services and Reimbursed Travel, partially offset by weaker
revenues from System sales.
Segment wise, revenues from
dipped 2.4% to $245.8 million. However,
Support, maintenance and services
revenues rose 19.3% to $531.1 million and
revenues went up 36.4% to $18.4 million.
Bookings revenues grew 9% to all-time high of $1.1 billion.
Bookings margin was $975 million or 88% of total bookings.
Total backlog increased 23% to $8.9 billion, which comprised of
$8.1 billion of contract backlog and $786.0 million of support
and maintenance backlog. Bookings performance led to a 23%
increase in total backlog.
Full Year Earnings and Revenues
For full year 2013, adjusted earnings per share rose 16.8% to
$1.32 from $1.13 a year ago and surpassed the Zacks Consensus
Estimate of $1.30. Adjusted net earnings escalated 17.4% to
$466.4 million from $397.2 million in 2012. However, reported
earnings were almost flat at $398.4 million or $1.13 per share
during the year.
Revenues in the year grew 9.2% to $2.9 billion, driven by rise in
Support, maintenance and services and Reimbursed Travel revenues,
partially offset by a fall in revenues from System sales.
Revenues were in line with the Zacks Consensus Estimate during
the year. Global revenues were up 11% for the year. Bookings
revenues were $3.77 billion, up 20% over 2012.
Gross margin for the quarter was 82.1%, up 370 basis points (bps)
from 78.4% in the prior-year quarter due to record software
levels and a lower mix of technology resale. For 2013, gross
margin was 82.3%, up 510 bps from 77.2% in 2012, also driven by
record software and lower technology resale.
Operating margin in the quarter was 25.6% (before share-based
compensation expense and the settlement charge), up 160 bps from
the prior-year quarter. For the full year, operating margins
increased 220 basis points to 25.1% due to a combination of
ongoing operating efficiencies, fall in lower margin technology
revenues and strength in software.
CERN had cash and cash equivalents of $202.4 million as of Dec
28, 2013, down from $317.1 million as of Dec 29, 2012. Total debt
declined to $165.8 million as of Dec 28, 2013 compared with
$196.1 million as of Dec 29, 2012. Consequently,
debt-to-capitalization ratio decreased 150 bps to 5.0% from 6.5%
as of Dec 29, 2012.
In 2013, cash flow from operating activities ebbed 1.8% to $695.9
million from $708.3 million in 2012. But capital expenditure
soared 92.4% to $352.9 million compared with $183.4 million a
year ago. As a result, free cash flow plunged 60.4% to $168.3
million from $424.7 million in 2012.
In December 2013, CERN's Board of Directors approved
authorization of stock repurchase of up to 217 million of the
company's common stock.
For the first quarter of 2014, CERN anticipates revenues between
$770 and $810 million while adjusted earnings are expected
between 33 and 34 cents per share, after share based compensation
expense. These compared with the Zacks Consensus Estimates of
$774 million 34 cents for revenues and earnings per share for the
The leading healthcare information technology ("HCIT") solutions
provider also expects new business bookings between $860 and $930
million for the quarter.
For full year 2014, CERN anticipates revenues in the range of
$3.2 to $3.4 billion. Adjusted earnings are expected between
$1.51 and $1.55, after share based compensation expense. These
compared with the Zacks Consensus Estimates of $3.3 billion and
$1.54 for revenues and earnings per share for the year.
For 2014, CERN anticipates stronger free cash flow, driven by
growth in operating cash flow, a decline in capital expenditures
and flat-to-slightly-higher capitalized software. The company
expects average capital expenditures in the range of $65 to $70
million per quarter, versus about $90 million in 2013.
Currently, CERN retains a Zacks Rank #3 (Hold). We believe
long-term investors may consider CERN, which serves a sizeable
installed hospital base that requires composite
clinically-oriented applications complying with "meaningful use"
needs, reimbursement difficulties and coding challenges. The
company has long-standing, integrated and seamless solutions for
both inpatient and ambulatory settings.
However, competition is fierce with well reputed names such as
Allscripts Healthcare Solutions
) and others. The intensity of competition may pressure both
pricing and margin. Stringent hospital budgets place further
pressure on pricing.